quizartinib
Phase 3- Indications
- Acute myeloid leukemia
Company intelligence / Profile preview
Ambit Biosciences
San Diego, California, United Statesdaiichisankyo.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Ambit's lead asset quizartinib showed promise in treating relapsed/refractory AML patients with FLT3 mutations—a population with poor prognosis and limited treatment options. The company had three internally developed programs at the time of acquisition. Quizartinib was considered a potential first-in-class therapy for this indication and drove Daiichi Sankyo's interest in the acquisition
- Therapeutic areas
- OncologyImmunology
- Modalities
- small molecules (kinase inhibitors)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
No major external pharma partnerships reported prior to acquisition.Financial advisors included Centerview Partners and Leerink Partners LLC during M&A process.Legal advisors included Cooley LLP.
Beyond the preview
Go deeper on Ambit Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambit Biosciences.